FeesSafety
Pluang+

Keros Therapeutics approves $5M share buyback after $20M milestone from Takeda deal

Company Fundamentals
16 Nov 2026, 23:01 WIB
GlobeNewsWire
View Source
Bullish
Keros Therapeutics approves $5M share buyback after $20M milestone from Takeda deal

Keros Therapeutics announced a new $5 million share repurchase program following a $20 million milestone payment from Takeda Pharmaceuticals after dosing the first patient in a clinical trial. This buyback program allows Keros to repurchase shares in the open market, depending on market conditions and other factors, but does not obligate the company to buy any specific amount. The milestone payment reflects progress in Keros' development of treatments targeting TGF-ß protein signaling disorders. This move supports shareholder value while Keros advances its clinical-stage biopharmaceutical pipeline, including therapies for Duchenne muscular dystrophy and myelofibrosis.

Keros Therapeutics' new $5 million share repurchase authorization is presented here with relevant market data for context. For readers following the health sector, 31 of 150 priced US stocks rose while 118 fell as of Nov 17, 2026 03:31 WIB. Notable movers include Summit Therapeutics Inc (SMMT) at USD 11.68 with a -17.46% change and Cassava Sciences Inc (FLNA) at USD 0.47 with a +10.56% change.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App